S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

ProPhase Labs Stock Forecast, Price & News

+0.19 (+1.65%)
(As of 06/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
96,600 shs
Average Volume
43,538 shs
Market Capitalization
$181.65 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive PRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter.

PRPH Stock Forecast (MarketRank)

Overall MarketRank

1.73 out of 5 stars

Medical Sector

876th out of 1,411 stocks

Pharmaceutical Preparations Industry

435th out of 672 stocks

Analyst Opinion: 2.3Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
ProPhase Labs logo

About ProPhase Labs (NASDAQ:PRPH)

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

PRPH Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Ex-Dividend for 6/3 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
$6.27 million
Pretax Margin


Sales & Book Value

Annual Sales
$79.04 million
Cash Flow
$0.39 per share
Book Value
$3.79 per share


Free Float
Market Cap
$181.65 million
Not Optionable

ProPhase Labs Frequently Asked Questions

Should I buy or sell ProPhase Labs stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ProPhase Labs stock.
View analyst ratings for ProPhase Labs
or view top-rated stocks.

What is ProPhase Labs' stock price forecast for 2022?

2 analysts have issued 1-year price objectives for ProPhase Labs' shares. Their PRPH stock forecasts range from $14.00 to $14.00. On average, they predict ProPhase Labs' share price to reach $14.00 in the next year. This suggests a possible upside of 19.4% from the stock's current price.
View analysts' price targets for ProPhase Labs
or view top-rated stocks among Wall Street analysts.

How has ProPhase Labs' stock performed in 2022?

ProPhase Labs' stock was trading at $7.17 at the beginning of 2022. Since then, PRPH shares have increased by 63.6% and is now trading at $11.73.
View the best growth stocks for 2022 here

When is ProPhase Labs' next earnings date?

ProPhase Labs is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for ProPhase Labs

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) posted its quarterly earnings data on Friday, May, 13th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.29. The business had revenue of $47.53 million for the quarter, compared to analysts' expectations of $24.31 million. ProPhase Labs had a net margin of 15.91% and a trailing twelve-month return on equity of 25.26%.
View ProPhase Labs' earnings history

How often does ProPhase Labs pay dividends? What is the dividend yield for ProPhase Labs?

ProPhase Labs declared a dividend on Friday, May 13th. Shareholders of record on Wednesday, May 25th will be given a dividend of $0.30 per share on Friday, June 3rd. The ex-dividend date is Tuesday, May 24th.
View ProPhase Labs' dividend history

Who are ProPhase Labs' key executives?

ProPhase Labs' management team includes the following people:
  • Mr. Ted William Karkus, Chairman & CEO (Age 63, Pay $941.4k)
  • Ms. Monica Brady, Chief Accounting Officer (Age 45, Pay $233.91k)
  • Mr. Billy Joe White, Chief Financial Officer (Age 61)
  • Ms. Alice Lioi, Exec. VP & Co-COO
  • Mr. Jason Karkus, Exec. VP & Co-COO
  • Mr. Sergio Miralles, Exec. VP & Chief Information Officer of ProPhase Diagnostics

What is Ted Karkus' approval rating as ProPhase Labs' CEO?

2 employees have rated ProPhase Labs CEO Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among ProPhase Labs' employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ProPhase Labs own?

What is ProPhase Labs' stock symbol?

ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."

Who are ProPhase Labs' major shareholders?

ProPhase Labs' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.31%), Renaissance Technologies LLC (1.44%), Avidian Wealth Solutions LLC (0.91%), Bank of New York Mellon Corp (0.28%), State Street Corp (0.20%) and Group One Trading L.P. (0.03%). Company insiders that own ProPhase Labs stock include Jason Michael Barr, Louis Md Gleckel and Ted William Karkus.
View institutional ownership trends for ProPhase Labs

Which institutional investors are selling ProPhase Labs stock?

PRPH stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Group One Trading L.P., and Simplex Trading LLC.
View insider buying and selling activity for ProPhase Labs
or view top insider-selling stocks.

Which institutional investors are buying ProPhase Labs stock?

PRPH stock was purchased by a variety of institutional investors in the last quarter, including Avidian Wealth Solutions LLC, Vanguard Group Inc., and State Street Corp.
View insider buying and selling activity for ProPhase Labs
or or view top insider-buying stocks.

How do I buy shares of ProPhase Labs?

Shares of PRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProPhase Labs' stock price today?

One share of PRPH stock can currently be purchased for approximately $11.73.

How much money does ProPhase Labs make?

ProPhase Labs (NASDAQ:PRPH) has a market capitalization of $181.65 million and generates $79.04 million in revenue each year. The company earns $6.27 million in net income (profit) each year or $1.009990 on an earnings per share basis.

How many employees does ProPhase Labs have?

ProPhase Labs employs 95 workers across the globe.

How can I contact ProPhase Labs?

ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The official website for ProPhase Labs is www.prophaselabs.com. The company can be reached via phone at (215) 345-0919, via email at [email protected], or via fax at 215-345-5920.

This page (NASDAQ:PRPH) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.